The Deal at a Glance

Agricultural processor ADM and precision-fermentation company The EVERY Company announced on July 14, 2026, that they will begin commercial-scale production of EVERY's OvoPro at ADM's corn-processing complex in Clinton, Iowa. It is the first US manufacturing site for the ingredient, which until now has relied entirely on contract fermentation capacity in Europe.

OvoPro is a recombinant ovalbumin — the dominant protein in conventional egg whites — produced by fermenting engineered yeast rather than collecting it from hens. It replicates the binding, gelling, foaming and whipping functions of egg whites across baked goods, bars, snacks, confectionery and pasta, and holds Generally Recognized as Safe (GRAS) status in the US following a "no questions" letter from the FDA. The companies expect volumes to grow roughly fivefold by the second half of 2027.

Why EVERY Builds Through Partners, Not Plants

EVERY does not own fermentation infrastructure, and that is deliberate. Wholly owned precision-fermentation plants routinely exceed $200 million in capital expenditure and take years to bring online — a timeline mismatched to how quickly demand for OvoPro has moved since it landed on national retail shelves. Instead, EVERY has built its supply chain by plugging into fermentation capacity that already exists inside larger industrial operators: first a pharmaceutical manufacturer in Bulgaria, now an agricultural processor in the American Midwest.

ADM's Clinton site is illustrative of the model. The facility already produces corn sweeteners, starches, beverage alcohol, corn oil, enzymes and ethanol, and recently underwent upgrades to its fermentation lines. For EVERY, that means access to scale and integrated corn feedstock without financing a dedicated facility. For ADM, it is a new commercial use for fermentation capacity it has already built.

The Bulgaria Precedent

The ADM deal follows a June 16, 2026 expansion with Bulgarian pharmaceutical group Huvepharma, whose subsidiary Biovet AD operates three fermentation sites — in Peshtera, Razgrad and Botevgrad — with more than 9 million litres of combined installed capacity, GMP-approved by both the EU and the US FDA. That agreement roughly quadrupled OvoPro output after EVERY's orders in the first four months of 2026 reached 550% of its entire 2025 volume, driven by national placement in Walmart and Target alongside e-commerce and foodservice demand.

Structural Tailwinds: An Egg Supply Under Pressure

The commercial urgency behind both deals traces back to the US egg supply itself. Recurring outbreaks of highly pathogenic avian influenza have depopulated more than 50 million egg-laying hens in recent waves, according to USDA figures, pushing wholesale egg prices above $5 per dozen in early 2024 — roughly 240% above 2021 averages — and costing American consumers an estimated $14.5 billion across 2024–25. That volatility has turned fermentation-made egg proteins from a niche formulation choice into a supply-chain hedge food manufacturers are actively qualifying.

A Crowded, Fast-Moving Field

EVERY is not alone in racing toward US commercial scale. Finland's Onego Bio received its own FDA "no questions" GRAS letter for its Bioalbumen ovalbumin in 2025, and industry trackers including Future Market Insights count Formo, Fybraworks Foods, FUMI Ingredients and Shiru among the companies developing competing fermentation-based egg and functional proteins. What distinguishes EVERY at this stage is retail distribution already in place and now two continents of contract manufacturing capacity to draw on — a combination few peers in the category have matched.

Implications for MENA Food Manufacturers

Gulf food manufacturers remain heavily reliant on imported eggs and egg derivatives for bakery, confectionery and processed food production — a dependency that mirrors the same shell-egg volatility now reshaping US formulation strategy. The EVERY-ADM model is relevant less for OvoPro itself than for the manufacturing logic behind it: accessing fermentation capacity through existing industrial processors, rather than financing new plants, is a path regional food companies and investors could apply to their own protein-diversification and food-security goals under Vision 2030, without the multi-year lead times full-scale fermentation infrastructure usually requires.

Editorial View

The ADM deal reads as a maturation signal for precision fermentation more broadly: an agricultural processor with no history in alternative proteins is now renting out fermentation capacity the way contract manufacturers do in biotech. That is a more durable growth model than any single funding round, and it is worth tracking whether other commodity processors follow ADM into this role. It is also worth remembering that a GRAS "no questions" letter reflects the FDA's lack of objection to a company's own safety conclusion — not a formal agency approval — a distinction that matters as more fermentation-made ingredients move toward mainstream shelves.